Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Skyhawk Therapeutics

Skyhawk Therapeutics?uq=U5Zpp9ZJ
PRIVATE STATUS
Early Stage VC LATEST DEAL TYPE
$100M LATEST DEAL AMOUNT
9 INVESTORS
Description

Developer of small molecule therapeutics designed to offer therapies that correct RNA expression. The company's therapeutics use proprietary technology that helps the rational design of small molecules that target specific binding pocket regions on RNA, using both sequence and structural specificity, at particular moments in the RNA splicing process, enabling physicians to target diseases driven by a type of RNA mis-splicing called exon skipping.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 35 Gatehouse Drive
  • Waltham, MA 02451
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Skyhawk Therapeutics’s full profile, request a free trial.

Skyhawk Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 26-Jun-2018 $100M 00000 Completed Generating Revenue
1. Seed Round 23-Jan-2018 000 000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Skyhawk Therapeutics Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Agent Capital Venture Capital Minority 000 0000 000000 0
Celgene Corporation Minority 000 0000 000000 0
Good Growth Capital Venture Capital Minority 000 0000 000000 0
GreatPoint Ventures Venture Capital Minority 000 0000 000000 0
ShangBay Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Skyhawk Therapeutics Executive Team (6)

Name Title Board
Seat
Contact
Info
Gary Martell Chief Financial Officer
Kathleen McCarthy Co-Founder & Chief Scientific Officer
Sergey Paushkin Ph.D Vice President & Director of Biology
Michael Luzzio Ph.D Vice President & Director of Chemistry
Maura McCarthy Director of Finance & Market Development
You’re viewing 5 of 6 executives. Get the full list »

Skyhawk Therapeutics Board Members (5)

Name Representing Role Since Contact
Info
Andrew Bedford Self Board Member 000 0000
Andrew Boyd Self Board Member 000 0000
Kevin Koch Ph.D Self Board Member 000 0000
Sean Reilly JD Self Board Member 000 0000
William Haney Self Co-Founder, Chief Executive Officer & Chairman 000 0000